Metreleptin for treating lipodystrophy

impact of metreleptin effect on hyperphagia and quality of life, because there is no simple relationship between eating less and quality of life. The committee acknowledged the expert comments and agreed that any improvements in hyperphagia would be important, but difficult to capture when considering the clinical benefits of metreleptin. The ERG noted that the NIH study measured food intake (kcal) per day in a subset of patients. This showed that, while intake decreased from baseline initially (4-month assessment), decreases were not statistically significant at the end of the year. Results from the NIH follow-up study showed that 99% of people who had metreleptin reported improvements in hyperphagia. The ERG highlighted that improvements were assessed in a review of medical notes and, although results suggested metreleptin improved hyperphagia, these judgements were not made using an objective measure. The patient experts stated that, since starting metreleptin, they had experienced a feeling of fullness after eating and that this had dramatically altered their lives. One patient expert also noted that, before their daughter started metreleptin, they had to lock cupboards because her intense hunger led her to search for food. But, since starting the treatment her hunger had reduced, and food seeking
